Seeking Alpha -The 'New' Celsion Could Be Worth $4 A Share
Celsion (CLSN) traded at $8 before the Phase III results were announced. After diluting by 50%, if it were to trade the same market cap on the hopes of ThermoDox possibly being approved again, we'd easily be back over $3 heading to $4. If the data continues to come out in favor of ThermoDox, as it has, we could reach these levels simply on the fact that another trial is taking place, with results (that would hopefully be positive) possibly not even being a factor. Also, directors are buying again. Director Albert Martinez just bought another 10,000 shares this week, following his buys that I pointed out last week. As I pointed out in my last article:
Said by a person with shaky command of the English language. Please, please, don't make ridiculous comments. CLSN FAILED its trials a few months ago, the question is whether or not it can be reborn or not.